Antistaphylococcal vaccines and immunoglobulins: Current status and future prospects

Drugs

Volumn 66, Issue 14, 2006, Pages 1797-1806

  Deresinski, Stan ^a,b,c  

^a STANFORD UNIVERSITY   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ALTASTAPH; ANTIINFECTIVE AGENT; AUREXIS; AUROGRAB; BSYX A110; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY T12; PAGIBAXIMAB; PLACEBO; STAPHVAX; STAPHYLOCOCCUS VACCINE; TEFIBAZUMAB; UNCLASSIFIED DRUG; VANCOMYCIN; VERONATE;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL ENDOCARDITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; GRAM NEGATIVE SEPSIS; HUMAN; IN VIVO STUDY; LOW BIRTH WEIGHT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTIBODIES, BACTERIAL; HUMANS; IMMUNIZATION, PASSIVE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; VACCINATION; VIRULENCE FACTORS;

STAPHYLOCOCCUS;

EID: 33750066338     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666140-00002     Document Type: Review

References (77)

1. Laupland KB, Church DL, Mucenski M, et al. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003; 187: 1452-9
2. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 to June 2004, issued October 2004. Am J Infect Control 2004; 32: 470-85
3. Wisplinghoff H, Bischoff T, Tallent SM. Nosocomial blood-stream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17
4. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436-44
5. Applebaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006; 12 Suppl. 1: 16-23
6. Klingenberg C, Aarag E, Rønnestad A, et al. Coagulase negative staphylococcal sepsis in neonates. Pediatr Infect Dis J 2005; 24: 817-22
7. Johnson-Robbins LA, el Mohandes AE, Simmens SJ, et al. Staphylococcus epidermidis sepsis in the intensive care nursery: a characterization of risk associations in infants < 1000g. Biol Neonate 1996; 69: 249-56
8. Etz H, Minh DB, Henics T, et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci U S A 2002; 99: 6573-8
9. O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 2004; 17: 218-34
10. Roghmann M, Taylor KL, Gupte A, et al. Epidemiology of capsular and surface polysaccharide in Staphylococcus aureus infections complicated by bactaeremia. J Hosp Infect 2005; 59: 27-32
11. Nabi Biopharmaceuticals. Nabi Biopharmaceuticals announces positive phase I results from its S. epidermidis PS-1 and S. aureus type 336 vaccine clinical trials [online]. Available from URL: http://phx.corporate-ir.net/phoenix.zhtml? c=100445&p=irol-newsArticle&ID=813506&highlight= [Accessed 2006 Feb 7]
12. Rivas JM, Speziale P, Patti JM, et al. MSCRAMM-targeted vaccines and immunotherapy for staphylococcal infection. Curr Opin Drug Discov Devel 2004; 7: 223-7
13. Josefsson E, Hartford O, O'Brien L, et al. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 2001; 184: 1572-80
14. Bloom B, Schelonka R, Kueser T, et al. Mulicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J 2005; 24: 858-66
15. Higgins J, Loughman A, van Kessel KP, et al. Clumping factor A of Staphylococcus aureus inhibits phagocytosis by human polymorphonuclear leucocytes. FEMS Microbiol Lett 2006; 258: 290-6
16. O'Brien LM, Walsh EJ, Massey RC, et al. Staphylococcus aureus clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. Cell Microbiol 2002; 4: 759-70
17. Xu Y, Rivas JM, Brown EL, et al. Virulence potential of the staphylococcal adhesin CNA in experimental arthritis is determined by its affinity for collagen. J Infect Dis 2004; 189: 2323-33
18. Endl J, Seidl HP, Fiedler F, et al. Chemical composition and structure of cell wall teichoic acids of staphylococci. Arch Microbiol 1983; 135: 215-23
19. Garcia-Lara J, Masalha M, Foster SJ. Staphylococcus aureus: the search for novel targets. Drug Discov Today 2005; 10: 643-51
20. Wiedenmaier C, Kokai-Kun JF, Kristian SA, et al. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat Med 2004; 10: 243-5
21. Weidenmaier C, Peschel A, Xiong YQ, et al. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. J Infect Dis 2005; 191: 1771-7
22. Gotz F. Staphylococcus and biofilms. Mol Microbiol 2002; 43: 1367-8
23. Davidson AL, Chen J. ATP-binding cassette transporters in bacteria. Annu Rev Biochem 2004; 73: 241-68
24. Otto M, Götz F. ABC transporters of staphylococci. Res Microbiol 2001; 152: 351-6
25. Kuroda M, Ohta T, Uchiyama I, et al. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 2001; 357: 1225-40
26. Miethke T, Duschek K, Wahl C, et al. Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1. Eur J Immunol 1993; 23: 1494-500
27. Kaneko J, Kamio Y. Bacterial two-component and heteroheptameric pore-forming cytolytic toxins: structures, poreforming mechanism, and organization of the genes. Biosci Biotechnol Biochem 2004; 68: 981-1003
28. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 2002; 359: 753-9
29. Fattom A, Schneerson R, Szu SC, et al. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun 1990; 58: 2367-74
30. Fattom A, Schneerson R, Watson DC, et al. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 1993; 61: 1023-32
31. Fattom A, Li X, Cho YH, et al. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. Vaccine 1995; 13: 1288-93
32. Welch PG, Fattom A, Moore J, et al. Safety and immunogenicity of Staphylococcus aureus type 5 polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. J Am Soc Nephrol 1996; 7: 247-53
33. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346: 491-6
34. Nabi Biopharmaceuticals. Nabi Biopharmaceuticals announces results of StaphVAX. confirmatory phase III clinical trial [online]. Available from URL: http://phx.corporate-ir.net/phoenix.zhtml?c=100445&p=irol- newsArticle&ID=776196&highlight= [Accessed 2006 Nov 1]
35. Nabi Biopharmaceuticals. Nabi Biopharmaceuticals announces completion of outside advisory panel assessment of Gram-positive program [online]. Available from URL: http://phx.corporate-ir.net/phoenix.zhtml?.c=100445&p=irol- newsArticle&ID=834257&highlight= [Accessed 2006 Mar 21]
36. Nabi Biopharmaceuticals. Altastaph® [online]. Available from URL: http://www.nabi.com/pipeline/pipeline.php?.id = 2 [Accessed 2006 Sep 3]
37. Inhibitex Inc. Inhibitex reports top-line results in phase III study of Veronate® [online]. Available from URL: http://phx.corporate-ir.net/phoenix. zhtml?.c=176944&p=irol-newsArticle&ID=837682&highlight= [Accessed 2006 Apr 3]
38. NeuTec Pharma plc. Aurograb® [online]. Available from URL: http://www.neutecpharma.com/aurograb.html [Accessed 2006 Sep 3]
39. Product candidates [online]. Available from URL: http://biosynexus.com/ productcandidates.html [Accessed 2006 Sep 3]
40. Benjamin DK, Schelonka R, White R, et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol 2006; 26: 290-5
41. Mandy GT, Weisman LE, Horwith G, et al. Safety of Staphylococcus aureus intravenous human immune globulin (Alta Staph) in very-low-birth-weight neonates [abstract no. 2023]. 2000 Pediatric Academic Societies' Annual Meeting; May 12-16; Boston [online]. Available from URL: http://www. pas-meeting.org/ [Accessed 2006 Sep 3]
42. Rupp ME, Lutz J, Dicpingaitis P, et al. Trial of Staphylococcus aureus capsular polysaccharide immune globulin in subjects with S. aureus bacteremia and persistent fever [abstract no. LB-14]. 43rd Meeting of the Infectious Disease Society of America; 2005 Oct 6-9; San Francisco
43. Vernachio J, Bayer AS, Le T, et al. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob Agents Chemother 2003; 47: 3400-6
44. Vernachio JH, Bayer AS, Ames B, et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother 2006; 50: 511-8
45. Kaufman D. Veronate Inhibitex. Curr Opin Invest Drugs 2006; 7: 172-9
46. Capparelli EV, Bloom BT, Kueser TJ, et al. Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth weight infants. Antimicrob Agents Chemother 2005; 49: 4121-7
47. De Jonge M, Burchfield D, Bloom B, et al. A phase III clinical trial of Veronate for prevention of staphylococcal sepsis in premature infants [poster no. 2857.187]. 2006 Pediatric Academic Societies' Annual Meeting; 2006 Apr 28-May 1; Baltimore (MD)
48. Hall AE, Domanski PJ, Patel PR, et al. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus. Infect Immun 2003; 71: 6864-70
49. Reilley S, Wenzel E, Reynolds L, et al. Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. Antimicrob Agents Chemother 2005; 49: 959-62
50. Domanski PJ, Patel PR, Bayer AS, et al. Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus. Infect Immun 2005; 73: 5229-32
51. Patti JM. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 2004; 22 Suppl. 1: S39-43
52. Weems J Jr, Steinberg JP, Filler S, et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50: 2751-5
53. Aurexis® in cystic fibrosis subjects chronically colonized with Staphylococcus aureus in their lungs [online]. Available from URL: http://clinicaltrials.gov/ct/show/NCT00198289?.order=1 [Accessed 2006 Sep 3]
54. Burnie JP, Matthews RC, Carter T, et al. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect Immun 2000; 68: 3200-9
55. Aurograb and vancomycin in MRSA infection [online]. Available from URL: http://clinicaltrials.gov/ct/show/NCT00217841?.order=1 [Accessed 2006 Sep 3]
56. Weisman LE, Schuman RF, Lukomska E, at al. Effectiveness and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibody. 2001 Pediatric Academic Societies' Annual Meeting; 2001 Apr 28-May 1; Baltimore (MD)
57. Biosynexus Inc. Product candidates. BSYX-A110 [online]. Available from URL: http://biosynexus.com/productcandi dates.html [Accessed 2006 Sep 3]
58. Weisman LE, Fischer GW, Mandy GT, et al. Safety and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibody in healthy adults [abstract no. 1572 ]. 2002 Pediatric Academic Societies' Annual Meeting; 2002 May 4-7; Baltimore (MD)
59. Weisman LE, Mandy GT, Garcia-Prats JA, et al. Safety and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibody for prevention of coagulase negative staphylococcal infection in very low birth weight infants: preliminary report [abstract no. 1800]. 2003 Pediatric Academic Societies' Annual Meeting; 2003 May 3-6; Seattle (WA)
60. Thackray H, Lassiter H, Walsh W, et al. Phase II randomized, double-blind, placebo-controlled, safety, pharmacokinetics, and clinical activity study in very low birth weight neonates of pagibaximab, a monoclonal antibody for the prevention of staphylococcal infection [abstract no. 3724.6]. 2006 Pediatric Academic Societies' Annual Meeting; 2006 Apr 29-May 2; San Francisco (CA)
61. Schroder A, Kland R, Peschel A, et al. Live cell imaging of phagosome maturation in Staphylococcus aureus infected human endothelial cells: small colony variants are able to survive in lysosomes. Med Microbiol Immunol. Epub 2006 Apr 5
62. Proctor RA, von Eiff C, Kahl BC, et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006; 4: 295-305
63. Mack D, Becker P, Chatterjee I, et al. Mechanisms of biofilm formation in Staphylococcus epidermidis and Staphylococcus aureus functional molecules, regulatory circuits, and adaptive responses. Int J Med Microbiol 2004; 294: 203-12
64. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol 2005; 3: 948-58
65. Nour El-Din AN, Shkreta L, Talbot BG, et al. DNA immunization of dairy cows with the clumping factor A of Staphylococcus aureus. Vaccine 2006; 24: 1997-2006
66. Shkreta L, Talbot BG, Diarra MS, et al. Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows. Vaccine 2004; 23: 114-26
67. Schaffer AC, Solinga RM, Cocchiaro J, et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun 2006; 74: 2145-53
68. Nilsson IM, Patti JM, Bremell T, et al. Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. J Clin Invest 1998; 101: 2640-9
69. Zhou H, Xiong ZY, Li HP, et al. An immunogenicity study of a newly fusion protein Can-FnBP vaccinated against Staphylococcus aureus in a mice model. Vaccine. Epub 2006 Mar 24
70. Hu DL, Omoe K, Sasaki S, et al. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. J Infect Dis 2003; 188: 743-52
71. Cui JC, Hu DL, Lin YC, et al. Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection. FEMS Immunol Med Microbiol 2005; 45: 45-51
72. Andrews MM, Parent EM, Barry M, et al. Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis, and treatment. Clin Infect Dis 2001; 32: 1470-9
73. Darenberg J, Söderquist B, Henriques Normark B, et al. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 2004; 38: 836-42
74. Gauduchon V, Cozon G, Vandenesch F, et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vivo. Clin Infect Dis 2004; 189: 346-53
75. Robbins JB, Schneerson R, Horwith G, et al. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines. Am Heart J 2004; 147: 593-8
76. Nabi Biopharmaceuticals. Clinical trials: StaphVAX [online]. Available from URL: http://www.nabi.com/physicians/ clinicaltrials.php [Accessed 2006 Sep 3]
77. Intercell's partner, Merck & Co. Inc., starts phase I clinical trial for Staphylococcus aureus vaccine based on Intercell's antigen [online]. Available from URL: http://www.biotech-intelligence.com/html/html/ 77f623af8e93bbed7c17cee003163e9f.html [Accessed 2006 25 Sep]